Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial

	Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial
	Li, Ning 2; Zhu, Jianqing 3; Yin, Rutie 4; Wang, Jing 5; Pan, Lingya 6; Kong, Beihua 7; Zheng, Hong 8; Liu, Jihong 9; Wu, Xiaohua 10; Wang, Li 11
刊名	ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
	2022-11-01
卷号	18
ISSN号	1743-7555
WOS研究方向	Oncology
语种	英语
出版者	WILEY
WOS记录号	WOS:000871956500189
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/130035]
专题	中国科学院合肥物质科学研究院
作者单位	1.Kunming Med Univ, Affiliated Hosp 3, Yunnan Canc Hosp, Kunming, Peoples R China 2.Chinese Acad Med Sci & Peking UnionMed Coll, Nat Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 4.Sichuan Univ, West China Univ Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ, Chengdu, Peoples R China 5.Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China 6.Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China 7.Shandong Univ, Qilu Hosp, Jinan, Peoples R China 8.Peking Univ Canc Hosp & Inst, Beijing, Peoples R China 9.Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China 10.Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Li, Ning,Zhu, Jianqing,Yin, Rutie,et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY,2022,18.
APA	Li, Ning.,Zhu, Jianqing.,Yin, Rutie.,Wang, Jing.,Pan, Lingya.,...&Wu, Lingying.(2022).Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial.ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY,18.
MLA	Li, Ning,et al."Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial".ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 18(2022).